Disclosed herein is a process for the preparation of highly pure 26-diisopropyl phenol (Formula I) which comprises reacting p-hydroxy benzoic acid (Formula II) with an alkylating agent in presence of aq. mineral acid followed by basification and subsequent washings to yield 4-hydroxy-35-diisopropylbenzoic acid (Formula III) free of dimer impurity 44'-oxydibenzoic acid of Formula IV ether impurity 35-di(propan-2-yl)-4-(propan-2-yloxy)benzoic acid of Formula V and the monoalkylated impurity 4-hydr...

The present invention pertains to pharmaceutical formulations containing propofol, methods for making such formulations, and methods for administering propofol at a pH above about 6.5, wherein the pain normally associated with propofol administration is reduced.

The present invention pertains to pharmaceutical formulations containing propofol methods for making such formulations and methods for administering propofol at a pH above about 6.5 wherein the pain normally associated with propofol administration is reduced.

The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug propofol analogs. This invention relates to a method for the production of a broad group of glycosylated propofol carbohydrate derivatives.

The invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. The semifluorinated alkane is comprised in the dispersed phase, which may also include an active pharmaceutical ingredient. One of the preferred active ingredients is propofol. The compositions are optionally heat sterilisable and can be used for pharmaceutical or cosmetic product applications, and administered topically, intravenously, or via other routes.

The invention provides novel pharmaceutical compositions comprising the active ingredient propofol. Preferably propofol is dissolved in at least one semifluorinated alkane. The compositions which are preferably liquid or gel-like may optionally comprise further excipients. They may be used as fill material in capsules as buccal or nasal sprays or as aerosols for pulmonary administration. They are particularly useful for the transmucosal administration of propofol.

A container storing an anesthetic is disclosed. The container is sealed by a closure and stores a liquid anesthetic solution. The anesthetic is from 0.1% to 10% by weight of the liquid anesthetic solution. The container is made of a material that is inert to the anesthetic and the closure is made of siliconized rubber or a metal. A concentration of the anesthetic in a liquid anesthetic solution stored in the container following a predetermined time period is at least 93% of a concentration of th...